1135686-60-0Relevant academic research and scientific papers
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease
Buckley, Benjamin J.,Majed, Hiwa,Aboelela, Ashraf,Minaei, Elahe,Jiang, Longguang,Fildes, Karen,Cheung, Chen-Yi,Johnson, Darren,Bachovchin, Daniel,Cook, Gregory M.,Huang, Mingdong,Ranson, Marie,Kelso, Michael J.
, (2019)
The oral K+-sparing diuretic amiloride shows anti-cancer side-activities in multiple rodent models. These effects appear to arise, at least in part, through moderate inhibition of the urokinase-type plasminogen activator (uPA, Ki = 2.4 μM), a p
Synthesis and preliminary evaluation of amiloride analogs as inhibitors of the urokinase-type plasminogen activator (uPA)
Matthews, Hayden,Ranson, Marie,Tyndall, Joel D.A.,Kelso, Michael J.
, p. 6760 - 6766 (2011/12/05)
A known side-activity of the oral potassium-sparing diuretic drug amiloride is inhibition of the enzyme urokinase-type plasminogen activator (uPA, K i = 7 μM), a promising anticancer target. Several studies have demonstrated significant antitum
